Pain Medication May Not Impair Driving
Posted on: Friday, 23 November 2007, 18:00 CST
Moderate, long-term pain medication use does not impair a person's ability to drive safely, researchers at Rush University Medical Center, Chicago, found.
Study leader Dr. Asokumar Buvanendran said that opioid pain relievers, such as morphine and other narcotics, carry warning labels urging patients not to drive or operate heavy machinery.
However, in a preliminary study, Buvanendran found no difference in the driving skills and reaction times of patients taking morphine compared to non-medicated drivers.
The study compared 51 patients chronically receiving oral morphine and 49 patients -- the control group -- receiving no pain medication. Each drove for approximately 12 minutes in a driving simulator that measured deviation from the center of the road, weaving, the number of accidents, and reaction time to surprise events.
The amount of weaving was 3.83 feet for both sets of drivers, and the opioid group had 5.33 collisions compared to the non-opioid group with 5.04, or no statistical difference. Reaction time also was similar for both groups: 0.69 seconds for the controlled group and 0.67 for the opioid group, Buvanendran said.
The findings were presented at the American Society of Anesthesiologists meeting in San Francisco.
Source: United Press International
Related Articles
- Javelin Completes Enrollment for Second Phase III Study of Pain Drug
- Ivivi Technologies' PEMF Signals Reduce Post Surgical Pain in Breast Augmentation Patients By 87 Percent, Study Reports
- St. Jude Medical Announces First Patient Implants in Clinical Study Evaluating Deep Brain Stimulation for Depression
- Cogentus Enrolls First European Patient in Phase III Study of Combination Drug
- Data From Pivotal Phase III Studies of Gilead's Letairis(R) (Ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients With WHO Functional Class II or III Symptoms Published in Circulation
- Carticept Medical Reports First Patients Treated in Pivotal Study of Agilus(TM) Therapy for Pain Associated With Ankle Osteoarthritis
- Fralex Reaches 100th Patient Milestone in Fibromyalgia Study
- Javelin Enrolls First Patient In Pivotal Phase III Postop Pain Study of Dyloject(TM)
- Pain Therapeutics Reports Oxytrex(TM) Results From a Large Trial in Patients With Moderate-to-Severe Osteoarthritic Pain
- Landmark Comparative Genomics Study Highlights the Importance of 'Junk' DNA in Higher Eukaryotes
 |
 |
User Comments (0)
RSS Feeds